223 related articles for article (PubMed ID: 26793191)
1. Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 Diabetes.
Pham MN; von Herrath MG; Vela JL
Front Immunol; 2015; 6():651. PubMed ID: 26793191
[TBL] [Abstract][Full Text] [Related]
2. Renegade homeostatic cytokine responses in T1D: drivers of regulatory/effector T cell imbalance.
Gupta S; Cerosaletti K; Long SA
Clin Immunol; 2014 Apr; 151(2):146-54. PubMed ID: 24576418
[TBL] [Abstract][Full Text] [Related]
3. Combination Therapy Using IL-2/IL-2 Monoclonal Antibody Complexes, Rapamycin, and Islet Autoantigen Peptides Increases Regulatory T Cell Frequency and Protects against Spontaneous and Induced Type 1 Diabetes in Nonobese Diabetic Mice.
Manirarora JN; Wei CH
J Immunol; 2015 Dec; 195(11):5203-14. PubMed ID: 26482409
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-2 and type 1 diabetes: new therapeutic perspectives.
Hartemann A; Bourron O
Diabetes Metab; 2012 Nov; 38(5):387-91. PubMed ID: 22771204
[TBL] [Abstract][Full Text] [Related]
5. Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes.
Yu A; Snowhite I; Vendrame F; Rosenzwajg M; Klatzmann D; Pugliese A; Malek TR
Diabetes; 2015 Jun; 64(6):2172-83. PubMed ID: 25576057
[TBL] [Abstract][Full Text] [Related]
6. Role of regulatory T cells for the treatment of type 1 diabetes mellitus.
Jaeckel E; Mpofu N; Saal N; Manns MP
Horm Metab Res; 2008 Feb; 40(2):126-36. PubMed ID: 18283631
[TBL] [Abstract][Full Text] [Related]
7. Interleukin 2 in the pathogenesis and therapy of type 1 diabetes.
Rosenzwajg M; Churlaud G; Hartemann A; Klatzmann D
Curr Diab Rep; 2014 Dec; 14(12):553. PubMed ID: 25344788
[TBL] [Abstract][Full Text] [Related]
8. Inducing and Administering Tregs to Treat Human Disease.
Perdigoto AL; Chatenoud L; Bluestone JA; Herold KC
Front Immunol; 2015; 6():654. PubMed ID: 26834735
[TBL] [Abstract][Full Text] [Related]
9. Development of Auto Antigen-specific Regulatory T Cells for Diabetes Immunotherapy.
Song J
Immune Netw; 2016 Oct; 16(5):281-285. PubMed ID: 27799873
[TBL] [Abstract][Full Text] [Related]
10. In autoimmune hepatitis type 1 or the autoimmune hepatitis-sclerosing cholangitis variant defective regulatory T-cell responsiveness to IL-2 results in low IL-10 production and impaired suppression.
Liberal R; Grant CR; Holder BS; Cardone J; Martinez-Llordella M; Ma Y; Heneghan MA; Mieli-Vergani G; Vergani D; Longhi MS
Hepatology; 2015 Sep; 62(3):863-75. PubMed ID: 25953611
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells expand antigen-specific Foxp3+ CD25+ CD4+ regulatory T cells including suppressors of alloreactivity.
Yamazaki S; Inaba K; Tarbell KV; Steinman RM
Immunol Rev; 2006 Aug; 212():314-29. PubMed ID: 16903923
[TBL] [Abstract][Full Text] [Related]
12. Type 1 diabetes and T regulatory cells.
ElEssawy B; Li XC
Pharmacol Res; 2015 Aug; 98():22-30. PubMed ID: 25959211
[TBL] [Abstract][Full Text] [Related]
13. Targeting CD44 augments the efficacy of Tregs in autoimmune diabetes.
Li CR; Mueller EE; Bradley LM
Immunol Lett; 2015 Feb; 163(2):199-205. PubMed ID: 25447401
[TBL] [Abstract][Full Text] [Related]
14. Alloantigen-specific CD4(+) regulatory T cells induced in vivo by ultraviolet irradiation after alloantigen immunization require interleukin-10 for their induction and activation, and flexibly mediate bystander immunosuppression of allograft rejection.
Hori T; Kuribayashi K; Saito K; Wang L; Torii M; Uemoto S; Kato T
Transpl Immunol; 2015 Jun; 32(3):156-63. PubMed ID: 25861842
[TBL] [Abstract][Full Text] [Related]
15. Cytokines and T regulatory cells in the pathogenesis of type 1 diabetes.
Kikodze N; Pantsulaia I; Rekhviashvili Kh; Iobadze M; Dzhakhutashvili N; Pantsulaia N; Kukuladze N; Bikashvili N; Metreveli D; Chikovani T
Georgian Med News; 2013 Sep; (222):29-35. PubMed ID: 24099812
[TBL] [Abstract][Full Text] [Related]
16. Human and Mouse CD8(+)CD25(+)FOXP3(+) Regulatory T Cells at Steady State and during Interleukin-2 Therapy.
Churlaud G; Pitoiset F; Jebbawi F; Lorenzon R; Bellier B; Rosenzwajg M; Klatzmann D
Front Immunol; 2015; 6():171. PubMed ID: 25926835
[TBL] [Abstract][Full Text] [Related]
17. Self-tolerance and autoimmunity in a regulatory T cell model.
Alexander HK; Wahl LM
Bull Math Biol; 2011 Jan; 73(1):33-71. PubMed ID: 20195912
[TBL] [Abstract][Full Text] [Related]
18. Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity.
Perret R; Sierro SR; Botelho NK; Corgnac S; Donda A; Romero P
Cancer Res; 2013 Nov; 73(22):6597-608. PubMed ID: 24048821
[TBL] [Abstract][Full Text] [Related]
19. Regulatory B and T cell responses in patients with autoimmune thyroid disease and healthy controls.
Kristensen B
Dan Med J; 2016 Feb; 63(2):. PubMed ID: 26836805
[TBL] [Abstract][Full Text] [Related]
20. Human Tregs Made Antigen Specific by Gene Modification: The Power to Treat Autoimmunity and Antidrug Antibodies with Precision.
Adair PR; Kim YC; Zhang AH; Yoon J; Scott DW
Front Immunol; 2017; 8():1117. PubMed ID: 28983300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
